Roche Signs an Agreement with Innovent to Develop Therapies for Hematological and Solid Cancers
Shots:
- Roche to receive upfront- development and commercial milestone payments plus royalties and retains option to license for each ex-China development and commercialization. Innovent to get non-exclusive access to certain technologies of Roche to discover and develop specific 2:1 T-cell bispecific Abs (TCB) and the universal CAR-T platform
- If Roche exercise the option- it will pay $140M as exercise fee- additional development- approval- sales milestone payments up to $1.96B (if all products are successfully developed and commercialized) plus royalties on each product to Innovent
- Roche's 2:1 T-cell bispecific Ab platform targeted to discover- develop and commercialize novel bispecific molecules including cell therapies for hematological and solid cancers
Click here to read full press release/ article
Ref: Roche | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com